Adverum Biotechnologies, Inc. (ADVM) Has Another Very Strong Trading Session

March 14, 2018 - By Ivan Hodges

The stock of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is a huge mover today! The stock increased 5.76% or $0.4 during the last trading session, reaching $7.35. About 1.34 million shares traded. Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has declined 30.48% since March 14, 2017 and is downtrending. It has underperformed by 47.18% the S&P500.
The move comes after 6 months positive chart setup for the $456.97 million company. It was reported on Mar, 14 by We have $8.01 PT which if reached, will make NASDAQ:ADVM worth $41.13 million more.

Analysts await Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to report earnings on May, 8. They expect $-0.29 earnings per share, up 23.68 % or $0.09 from last year’s $-0.38 per share. After $-0.32 actual earnings per share reported by Adverum Biotechnologies, Inc. for the previous quarter, Wall Street now forecasts -9.38 % EPS growth.

More notable recent Adverum Biotechnologies, Inc. (NASDAQ:ADVM) news were published by: which released: “Adverum Biotechnologies Announces Completion of Dosing of First Cohort of …” on February 26, 2018, also with their article: “Adverum Biotechnologies Announces Closing of $69 Million Public Offering” published on February 12, 2018, published: “3 Growth Stocks for In-the-Know Investors” on March 14, 2018. More interesting news about Adverum Biotechnologies, Inc. (NASDAQ:ADVM) were released by: and their article: “Adverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and …” published on March 06, 2018 as well as‘s news article titled: “Premarket analyst action – healthcare” with publication date: February 15, 2018.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $456.97 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.